Buprenorphine

When ATH:
N02AE01

Characteristic.

The white crystalline powder. It is soluble in water, soluble in alcohol.

Pharmacological action.
Analgesic (opioid).

Application.

Painful high intensity syndrome (after surgery, in cancer patients, myocardial infarction, počečnaâ how, burns).

Contraindications.

Hypersensitivity, physical dependence.

Restrictions apply.

Respiratory and renal failure, traumatic brain injury, pregnancy, lactation.

Pregnancy and breast-feeding.

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

Side effects.

Headache, dizziness, Sweating, dry mouth, nausea, vomiting.

Cooperation.

Strengthens (mutually) the main and side effects, as well as the toxicity of MAO inhibitors and funds, CNS depressants (trankvilizatorov, neuroleptics and others.).

Overdose.

Manifested depression of the respiratory center.

Treatment: vvodyat naloxone, and symptomatic agents.

Dosing and Administration.

B /, / m, sublingually. Single dose for adults with in / and the / m - 0.3-0.45 mg. If necessary, the injection was repeated every 6-8 hours.

With sublingual - 0.2-0.4 mg every 6-8 hours between the intake of.

Cooperation